IQVIA Holdings Inc. $IQV Shares Bought by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 6,125.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,980 shares of the medical research company’s stock after acquiring an additional 4,900 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in IQVIA were worth $849,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. J. Safra Sarasin Holding AG increased its holdings in shares of IQVIA by 174.3% during the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock worth $2,891,000 after buying an additional 8,151 shares during the last quarter. CWM LLC lifted its holdings in IQVIA by 23.9% in the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock valued at $12,585,000 after acquiring an additional 10,762 shares during the last quarter. Calamos Advisors LLC lifted its holdings in IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock valued at $42,536,000 after acquiring an additional 137,441 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new position in IQVIA in the fourth quarter worth approximately $15,724,000. Finally, HF Advisory Group LLC increased its stake in IQVIA by 1,791.6% during the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock worth $34,852,000 after acquiring an additional 146,444 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $210.63 on Friday. The stock has a market capitalization of $35.15 billion, a price-to-earnings ratio of 26.10, a price-to-earnings-growth ratio of 1.85 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The business has a 50-day moving average of $184.48 and a 200 day moving average of $188.03. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a stock buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IQV. HSBC reaffirmed a “buy” rating and issued a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. Finally, Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.71.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.